MDI Therapeutics
Novi, US · Founded 2015 · Michigan corporation
MDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 1 of 2 rounds · 2018–2022
▶$1.7MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
- Stephen C BenoitExecutive Officer, Director
- Duane E DayExecutive Officer
- Grazia PiizziDirector
- Daniel A LawrenceExecutive Officer
- David GinsburgDirector
- Offering amount
- $9.7M
- Amount sold
- $1.7M
- First sale
- Feb 2022
- Incorporated
- Corporation, Michigan, 2022
- Federal exemptions
- 06b
▶$1.6MofferedFeb 2018 · PharmaceuticalsRule 506(b)
- Daniel Lawrence, Ph.D.Executive Officer, Director
- Duane DayExecutive Officer, Director
- Stephen BenoitExecutive Officer, Director
- Offering amount
- $1.6M
- Minimum investment
- $250K
- Incorporated
- Corporation, Michigan, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with MDI Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $216.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does MDI Therapeutics do?
- MDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
- How much funding has MDI Therapeutics raised?
- MDI Therapeutics has disclosed $1.7M raised across 1 of its 2 known rounds.
- Where is MDI Therapeutics headquartered?
- MDI Therapeutics is headquartered in Novi, US.